Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Jo Shorthouse

London, U.K
Jo Shorthouse is features editor for Scrip Intelligence and manages the Scrip 100 publication. Jo has covered the biopharmaceutical industry and related service industries since 2008 when she edited Good Clinical Practice journal followed by Scrip Clinical Research. Before this, she worked at various publications covering topics such as chemical logistics, the advertising industry and the property market.
Advertisement
Set Alert for Articles By Jo Shorthouse

Latest From Jo Shorthouse

Biosimilar Infliximab Success Paves The Way For Adalimumab In Europe

With the impending European launch of Humira biosimilar adalimumab in October, Scrip talks to some of those in the region that have experience in launching commercially successful biosimilars about uptake, discounts and payer attitudes.

Biosimilars Commercial

Mavenclad Is Merck KGaA Bright Spot As Q2 Sales Slip

With strong quarterly sales of Mavenclad in Europe, and a recent re-filing of the drug with the FDA, Merck KGaA continues to play the waiting game for top-line growth to return as it banks on the new addition to its MS franchise.

Companies Sales & Earnings

Generic Blow Looms For Lundbeck

With a new CEO taking the reins in September and a candidate entering the clinic for Parkinson’s disease, Lundbeck has opportunities for refreshment, both in the pipeline and the boardroom. But with generic competition battering down the company’s financial outlook, it may not be enough to bring the market along for the ride.

Sales & Earnings Commercial

Jardiance Is The Star Of Boehringer’s Show, But Micardis Drag Spoils The Party

Jardiance growth offsets Micardis woes as the German major updates the industry on its H1.

Commercial Companies

Anima Biotech: Lighting The Way In Protein Translation

Emerging Company Profile: With a new partner in Eli Lilly, Anima Biotech and its disruptive technology that controls protein translation is starting to make waves as it urges the industry to see the light.

Innovation StartUps and SMEs

Buoyant Biotech Funding Environment Directly Impacts CRO Q2s

The contract services industry is reaping the rewards of a resilient biotech funding environment, re-accelerating growth in the sector.

Sales & Earnings Commercial
See All
Advertisement
UsernamePublicRestriction

Register